San Francisco – March 22, 2017 – Cooley advised Kite Pharma on its $409.7 million shelf-takedown offering of 5,462,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 712,500 additional shares.
Jefferies acted as the sole book-running manager for the offering. Cowen and Company, RBC Capital Markets and Guggenheim Securities acted as co-managers.
Kite Pharma, which trades on The NASDAQ Global Select Market as “KITE,” is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to target and kill cancer cells.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.